Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4512)
°¨¿°Áúȯ (322)
°ñÁúȯ Ä¡·á (48)
´ç´¢º´ (164)
¹é½Å (169)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (49)
ºñó¹æ ÀǾàǰ (149)
¼öÀÇÇÐ (17)
½Å°æÁúȯ (179)
½Å¾à°³¹ß (1306)
¾ÏÄ¡·á (856)
¾à¹°Àü´Þ (179)
ÀǾàǰ ±ÔÁ¦È¯°æ (105)
Á¤½ÅÁúȯ (88)
Á¦³×¸¯ ÀǾàǰ (116)
Á¦¾àȸ»çºÐ¼® (488)
󹿾à (128)
Áö¿ªº°°Ë»ö
ÃâÆÇ»ç¿¡¼­ ã±â

½Å°æÁúȯ ½ÃÀåÁ¶»çº¸°í¼­

½Å°æÁúȯ ½ÃÀåÀ» Á¶»ç ºÐ¼®ÇÑ ÀÚ·á·Î ½ÃÀå ±Ô¸ð, »ê¾÷ ºÐ¼®, ÇâÈÄ ½ÃÀå ¿¹Ãø µîÀÇ ³»¿ëÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù.
º¸°í¼­¿¡ µû¶ó¼­ ÁÖ¿ä ±â¾÷ ºÐ¼®, °æÀïȯ°æ ºÐ¼®, ¿¬±¸°³¹ß ÇöȲ, ¿µ¾÷ Àü·«, ±â¾÷ Á¦ÈÞ ÇöȲÀ» Æ÷ÇÔÇÏ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù.

»ó¼¼ºÐ·ù
Á¦¸ñ°Ë»ö
1 - 25 ¸®ºä (Àüü£º 175 °Ç) Á¤·Ä Ç¥½Ã °Ç¼ö
Evolution in the Pain Therapy Drugs Market: Nociceptive and Neuropathic Drug Development
»ùÇÃ
»óǰÄÚµå :227842
ÅëÁõ Ä¡·áÁ¦(Pain Therapy Drugs) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇϰí, ½ÃÀå °³¿ä, ÅëÁõÀÇ Á¾·ù, Ä¡·á ¿É¼Ç, ÇâÈÄ Àü¸Á, ÀÓ»ó°³¹ßÁßÀÎ 75°³ÀÇ ÅëÁõ Ä¡·á¿ë ¾àÁ¦ ¼Ò°³ µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,265
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç Espicom Business Intelligence
ÆäÀÌÁö¼ö Pages: 126
Drug Delivery in Central Nervous System Diseases - technologies, markets and companies
»óǰÄÚµå :70934
ÁßÃ߽Űæ°è ÁúȯÀÇ ¾à¹°Àü´Þ ±â¼ú, ½ÃÀå ¹× °ü·Ã±â¾÷ Á¤º¸¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,000
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç Jain Pharmabiotech
ÆäÀÌÁö¼ö  
Alzheimer disease - new drugs, markets and companies
»óǰÄÚµå :70927
¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ Ä¡·á¾à °³¹ß µ¿Çâ ¹× °ü·Ã ±â¾÷ÀÇ Á¤º¸ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç Jain Pharmabiotech
ÆäÀÌÁö¼ö  
Neuroprotection - Drugs, Markets and Companies
»óǰÄÚµå :70919
¹ßÀÛÀ̳ª ½Å°æ°è ¼Õ»ó µîÀÇ ±Þ¼º Áúȯ, ½Å°æº¯¼º ÀåÇØ µîÀÇ ¸¸¼º ÁúȯÀÇ Ä¡·á¿¡ À־ ½Å°æ º¸È£ÀÇ ¿ªÇÒ¿¡ ´ëÇØ Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,000
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç Jain Pharmabiotech
ÆäÀÌÁö¼ö  
Multiple Sclerosis Treatment: World Drug Market 2012-2022
»ùÇÃ
»óǰÄÚµå :226946
´Ù¹ß¼º °æÈ­Áõ(Multiple Sclerosis) Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, Àü¼¼°è ¹× ÁÖ¿ä ±¹°¡¸¦ ´ë»óÀ¸·Î 2022³â±îÁö ÇâÈÄ 10³â°£ÀÇ ½ÃÀå ¸ÅÃâ ¼ºÀå ¿¹Ãø, ÇöÀçÀÇ ÁÖ¿ä Á¦Ç° ¹× Á¦¾à¾÷üÀÇ µ¿Ç⠺м®, Áõ»ó ÁøÇàÀÇ ¾ïÁ¦, Àç¹ß ¹æÁö¸¦ À§ÇÑ ½Å¾à °³¹ß ÇöȲ¿¡ ´ëÇÑ ÃֽŠÁ¶»ç Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,642
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Visiongain
ÆäÀÌÁö¼ö 116 Pages
Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted
»ùÇÃ
»óǰÄÚµå :224309
ÁßÃ߽Űæ°è Áúȯ ÀÓ»ó½ÃÇè Æò°¡ÁöÇ¥(Endpoint)¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, ¾ÈÀü¼º°ú À¯È¿¼º¿¡ ÁßÁ¡À» µÐ ÁßÃ߽Űæ°è Áúȯ ½ÃÆÇ ÀǾàǰ¿¡ ´ëÇØ ºÐ¼®ÇßÀ¸¸ç, Á¦Ç° ÇÁ·ÎÆÄÀϸµ, Áúȯº° Á¦Ç° ÆÄÀÌÇÁ¶óÀÎ Æò°¡, ÁÖ¿ä ±â¾÷ °³¿ä µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç GBI Research
ÆäÀÌÁö¼ö Pages: 216
Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
»ùÇÃ
»óǰÄÚµå :219213
¼¼°èÀÇ ÁßÃ߽Űæ°è Áúȯ(Central Nervous System Disorders) Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, ½ÃÀå Àüü ¸ÅÃâ µ¿Çâ°ú À¯·´ ¹× ¹Ì±¹, ÀϺ»ÀÇ Áö¿ªº° ȯ°æ, °¢ Áúȯº° ½ÃÀå µ¿Çâ, Á¦Ç° °³¹ß ÆÄÀÌÇÁ¶óÀÎ, ½ÃÀå ÁøÃâ±â¾÷ °³¿ä¿Í ½ÃÀå Á¡À¯À² µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç GBI Research
ÆäÀÌÁö¼ö Pages: 230
»ùÇÃ
»óǰÄÚµå :229417
½Å°æº´Áõ ÅëÁõ(Neuropathic Pain) ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷°ú Á¦Ç° ¶óÀÎ SWOT ºÐ¼®, ÁÖ¿ä ±â¾÷ ºê·£µå ¼ö¸í ÁÖ±â¿Í Á¦Ç° ¶óÀÎ °ü¸® Àü·«, ½Å°æº´Áõ ÅëÁõ ºÐ¾ßÀÇ È°¹ßÇÑ ±â¾÷ Àü·« µ¿Çâ°ú ÃÖ±Ù ¶óÀ̼¾½º °è¾àÀÇ ¿µÇâ, ÇâÈÄ ±âȸ¿Í °úÁ¦¿¡ ´ëÇÑ ±â¾÷ÀÇ ´ëÀÀ ¹æ¹ý µîÀ» »ó¼¼ÇÏ°Ô Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,800
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 40
Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth
»ùÇÃ
»óǰÄÚµå :219212
¼¼°èÀÇ ½Å°æº¯¼ºÁúȯ(Neurodegenerative Disease) Ä¡·áÁ¦ ½ÃÀåÀ» Á¶»ç ºÐ¼®Çϰí, ½ÃÀå Àüü µ¿Çâ°ú À¯·´ ¹× ¹Ì±¹, ÀϺ» µîÀÇ Áö¿ªº° ȯ°æ, Ä¡·á ºÐ¾ßº° ½ÃÀå ¼ºÀå ÃËÁø¿äÀΰú ÀúÇØ¿äÀÎ, Á¦Ç° °³¹ß ÆÄÀÌÇÁ¶óÀÎ µ¿Çâ, °æÀï»ç °³¿ä¿Í M&A µ¿Çâ µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç GBI Research
ÆäÀÌÁö¼ö Pages: 145
Parkinson's Disease: World Drug Market 2011-2021
»ùÇÃ
»óǰÄÚµå :220572
ÆÄŲ½¼º´(Parkinson''s Disease) ½ÃÀåÀ» Á¶»ç ºÐ¼®Çϰí, ½ÃÀå ¸ÅÃâ, 2021³â±îÁöÀÇ ¿¹Ãø, ½ÃÀå Á¡À¯À², SWOT ºÐ¼®À» Æ÷ÇÔÇÑ Á¤¼º ºÐ¼®, ¿¬±¸ °³¹ß µ¿Çâ µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,642
¹ßÇàÀÏ 2011³â 09¿ù
¸®¼­Ä¡»ç Visiongain
ÆäÀÌÁö¼ö 142 Pages
Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :214925
¼¼°èÀÇ ·ç°Ô¸¯º´(ALS : Amyotrophic Lateral Sclerosis) Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹ÃøÀ» ½Ç½ÃÇϰí, ½ÃÀå Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀÇ Æò°¡ ºÐ¼®, ÇâÈÄ ½ÃÀå °æÀï, ±â¾÷ °³¿ä¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 09¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 80
Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :213630
½Å°æº´Áõ ÅëÁõ(Neuropathic Pain) Ä¡·áÁ¦ ½ÃÀå °³¿ä, ÁÖ¿ä ±¹°¡ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, °æÀï µ¿Çâ, ÆÄÀÌÇÁ¶óÀÎ ÀǾàǰ °³¿ä, °¢»çÀÇ Àü·« µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 09¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 113
Global CNS Drug Market: Strategic Assessments of Leading Suppliers
»ùÇÃ
»óǰÄÚµå :216709
¼¼°è ÁßÃ߽Űæ°è(CNS) Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä °ø±Þ¾÷ü¿¡ ´ëÇØ ½ÇÀû, ´É·Â, ¸ñÇ¥, Àü·«, Ä«Å×°í¸®º°, Áö¿ªº° ¸ÅÃâ ¿¹Ãø µî Æ÷°ýÀû Á¤º¸¸¦ Á¦°øÇϰí, °ø±Þ¾÷ü, ÇâÈÄ ½ÃÀå ÁøÃâÀ» °í·ÁÇϰí ÀÖ´Â ±â¾÷, °æÀï»ç µîÀ» Áö¿øÇϱâ À§ÇÑ ÆÇ¸Å, Á¦ÈÞ¿Í Àμö, ¸¶ÄÉÆÃ, R&D Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 9,800
¹ßÇàÀÏ 2011³â 09¿ù
¸®¼­Ä¡»ç Venture Planning Group
ÆäÀÌÁö¼ö  
Clinical Trial Recruitment in Central Nervous System Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia
»ùÇÃ
»óǰÄÚµå :212665
2000-2009³â¿¡ °³½ÃµÈ Àüü ÁßÃ߽Űæ°èÁúȯ(Central Nervous System Disorders) ÀÓ»ó½ÃÇèÀ» ºÐ¼®Çϰí, ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, °£Áú, Á¤½ÅºÐ¿­Áõ, ¿ì¿ïÁõ µî ÁÖ¿ä 5°³ ÀûÀÀ¿¡ ´ëÇÑ °¢°¢ÀÇ ÀÓ»ó½ÃÇè µ¿Çâ, ºê¶óÁú, Àεµ, Áß±¹ÀÇ µ¿Çâ, Æò±Õ ÇÇÇèÀÚ¼ö µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 09¿ù
¸®¼­Ä¡»ç GBI Research
ÆäÀÌÁö¼ö Pages: 97
Restless Leg Syndrome (RLS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
»ùÇÃ
»óǰÄÚµå :214924
1 ¸ñÂ÷
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 08¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 67
Extended Release CNS Therapeutics: Drugs, Indications, Markets and Prospects
»ùÇÃ
»óǰÄÚµå :209135
¼­¹æÇü ÁßÃ߽Űæ°è Ä¡·áÁ¦¿¡ ´ëÇØ Æ÷°ýÀûÀ¸·Î Á¶»çºÐ¼®ÇßÀ¸¸ç, ±â¼ú °³¿ä, Á¦Ç° µ¿Çâ, ÁßÃ߽Űæ°è ºÎ¹®ÀÇ °³¿ä¿Í ÁøÃâ ±â¾÷ °³¿ä µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,850
¹ßÇàÀÏ 2011³â 08¿ù
¸®¼­Ä¡»ç Greystone Research Associates
ÆäÀÌÁö¼ö  
Requip (ropinirole) - Analysis and Estimates from 2002 to 2020
»ùÇÃ
»óǰÄÚµå :217363
ÆÄŲ½¼º´ Ä¡·áÁ¦ÀÎ Requip (ropinirole)ÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹ÃøÀ» Á¶»çÇϰí, ½ÃÀå Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀÇ Æò°¡ ºÐ¼®°ú ÇâÈÄ ½ÃÀå °æÀï, ±â¾÷ °³¿ä¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 38
Zelapar - Analysis and Estimates from 2002 to 2020
»ùÇÃ
»óǰÄÚµå :217362
ÆÄŲ½¼º´ Ä¡·áÁ¦ÀÎ ZelaparÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹ÃøÀ» Á¶»çÇϰí, ½ÃÀå Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀÇ Æò°¡ ºÐ¼®°ú ÇâÈÄ ½ÃÀå °æÀï, ±â¾÷ °³¿ä¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 31
Safinamide - Analysis and Estimates from 2012 to 2020
»ùÇÃ
»óǰÄÚµå :217361
ÆÄŲ½¼º´ Ä¡·áÁ¦ÀÎ SafinamideÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹ÃøÀ» Á¶»çÇϰí, ½ÃÀå Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀÇ Æò°¡ ºÐ¼®°ú ÇâÈÄ ½ÃÀå °æÀï, ±â¾÷ °³¿ä¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 35
Preladenant- Analysis and Estimates from 2014 to 2020
»ùÇÃ
»óǰÄÚµå :217359
ÆÄŲ½¼º´ Ä¡·áÁ¦ÀÎ PreladenantÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹ÃøÀ» Á¶»çÇϰí, ½ÃÀå Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀÇ Æò°¡ ºÐ¼®°ú ÇâÈÄ ½ÃÀå °æÀï, ±â¾÷ °³¿ä¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 34
Pardoprunox - Analysis and Forecasts from 2013 to 2020
»ùÇÃ
»óǰÄÚµå :217358
ÆÄŲ½¼º´ Ä¡·áÁ¦ÀÎ PardoprunoxÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 35
Mirapex ER - Analysis and Estimates from 2009 to 2020
»ùÇÃ
»óǰÄÚµå :217357
ÆÄŲ½¼º´ Ä¡·áÁ¦ÀÎ Mirapex ERÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹ÃøÀ» Á¶»çÇϰí, ½ÃÀå Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀÇ Æò°¡ ºÐ¼®°ú ÇâÈÄ ½ÃÀå °æÀï, ±â¾÷ °³¿ä¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 34
Mirapex - Analysis and Estimates from 2002 to 2020
»ùÇÃ
»óǰÄÚµå :217356
ÆÄŲ½¼º´ Ä¡·áÁ¦ÀÎ MirapexÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹ÃøÀ» Á¶»çÇϰí, ½ÃÀå Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀÇ Æò°¡ ºÐ¼®°ú ÇâÈÄ ½ÃÀå °æÀï, ±â¾÷ °³¿ä¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 35
Requip XL - Analysis and Estimates from 2007 to 2020
»ùÇÃ
»óǰÄÚµå :217355
ÆÄŲ½¼º´ Ä¡·áÁ¦ÀÎ Requip XLÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹ÃøÀ» Á¶»çÇϰí, ½ÃÀå Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀÇ Æò°¡ ºÐ¼®°ú ÇâÈÄ ½ÃÀå °æÀï, ±â¾÷ °³¿ä¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 35
Trerief - Analysis and Estimates from 2009 to 2020
»ùÇÃ
»óǰÄÚµå :217354
ÆÄŲ½¼º´ Ä¡·áÁ¦ÀÎ TreriefÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹ÃøÀ» Á¶»çÇϰí, ½ÃÀå Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀÇ Æò°¡ ºÐ¼®°ú ÇâÈÄ ½ÃÀå °æÀï, ±â¾÷ °³¿ä¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 25